Brought to you by 
Merck licenses Celltech's asthma treatment for $50 million
24 May 2013
Executive Summary
Merck has licensed the exclusive, worldwide rights to Celltech's CDP-840 asthma treatment, an anti-inflammatory agent set to begin Phase II in September '94, in exchange for nearly $50 million in research payments.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck licenses Celltech's asthma treatment for $50 million
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice